Literature DB >> 17996873

PAR-2 mediates increased inflammatory cell adhesion and neointima formation following vascular injury in the mouse.

Gail M Tennant1, Roger M Wadsworth, Simon Kennedy.   

Abstract

Activation of PAR-2 in the vasculature affects vascular tone and adhesion of leukocytes to the endothelium. Since adhesion of leukocytes is increased following vascular injury and is important in determining the extent of neointima formation, we hypothesised that mice lacking PAR-2 may have reduced neointima formation following vascular injury. PAR-2 activating peptides and trypsin induced endothelium-dependent relaxation of mouse carotid artery which was absent in the knockout mouse. Lack of a PAR-2 receptor did not affect lymphocyte adhesion under basal conditions, but reduced the contractile response produced by lymphocytes. Twenty-eight days after denuding injury, vessel contraction to lymphocytes was reduced in both strains while lymphocyte adhesion was significantly greater in PAR-2(+/+) mice compared to the PAR-2 knockout mice. Neointimal area was markedly reduced in the PAR-2 knockout mouse. Our data show that PAR-2 modulates inflammatory cell adhesion when stimulated and in mice lacking the PAR-2 receptor, adhesion to injured vessels is reduced with a consequent reduction in neointima formation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17996873     DOI: 10.1016/j.atherosclerosis.2007.09.043

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  8 in total

1.  A direct oral factor Xa inhibitor edoxaban ameliorates neointimal hyperplasia following vascular injury and thrombosis in apolipoprotein E-deficient mice.

Authors:  Yoshiyuki Morishima; Yuko Honda
Journal:  J Thromb Thrombolysis       Date:  2018-07       Impact factor: 2.300

2.  Protease-activated receptor-2 modulates protease-activated receptor-1-driven neointimal hyperplasia.

Authors:  Leila M Sevigny; Karyn M Austin; Ping Zhang; Shogo Kasuda; Georgios Koukos; Sheida Sharifi; Lidija Covic; Athan Kuliopulos
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-09-22       Impact factor: 8.311

3.  Serpin treatment suppresses inflammatory vascular lesions in temporal artery implants (TAI) from patients with giant cell arteritis.

Authors:  Hao Chen; Donghang Zheng; Sriram Ambadapadi; Jennifer Davids; Sally Ryden; Hazem Samy; Mee Bartee; Eric Sobel; Erbin Dai; Liying Liu; Colin Macaulay; Anthony Yachnis; Cornelia Weyand; Robert Thoburn; Alexandra Lucas
Journal:  PLoS One       Date:  2015-02-06       Impact factor: 3.240

4.  New quantitative trait loci for carotid atherosclerosis identified in an intercross derived from apolipoprotein E-deficient mouse strains.

Authors:  Jessica S Rowlan; Zhimin Zhang; Qian Wang; Yan Fang; Weibin Shi
Journal:  Physiol Genomics       Date:  2013-03-05       Impact factor: 3.107

5.  Blood pressures, heart rate and locomotor activity during salt loading and angiotensin II infusion in protease-activated receptor 2 (PAR2) knockout mice.

Authors:  John J McGuire; Bruce N Van Vliet; Sarah J Halfyard
Journal:  BMC Physiol       Date:  2008-10-21

Review 6.  Characterization and Functions of Protease-Activated Receptor 2 in Obesity, Diabetes, and Metabolic Syndrome: A Systematic Review.

Authors:  Satomi Kagota; Kana Maruyama; John J McGuire
Journal:  Biomed Res Int       Date:  2016-02-23       Impact factor: 3.411

7.  High Fat Diet Attenuates the Anticontractile Activity of Aortic PVAT via a Mechanism Involving AMPK and Reduced Adiponectin Secretion.

Authors:  Tarek A M Almabrouk; Anna D White; Azizah B Ugusman; Dominik S Skiba; Omar J Katwan; Husam Alganga; Tomasz J Guzik; Rhian M Touyz; Ian P Salt; Simon Kennedy
Journal:  Front Physiol       Date:  2018-02-09       Impact factor: 4.566

8.  PEA-15 (Phosphoprotein Enriched in Astrocytes 15) Is a Protective Mediator in the Vasculature and Is Regulated During Neointimal Hyperplasia.

Authors:  Fiona H Greig; Simon Kennedy; George Gibson; Joe W Ramos; Graeme F Nixon
Journal:  J Am Heart Assoc       Date:  2017-09-11       Impact factor: 5.501

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.